M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8
Interventions: DRUG: Bintrafusp Alfa|DRUG: Eribulin Mesylate
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)